Meridian Wealth Advisors LLC Invests $385,000 in Inhibrx, Inc. (NASDAQ:INBX)

Meridian Wealth Advisors LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $385,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in INBX. Exchange Traded Concepts LLC bought a new stake in shares of Inhibrx during the 4th quarter worth approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Inhibrx during the 4th quarter worth approximately $348,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Inhibrx in the 4th quarter valued at approximately $47,000. Rhumbline Advisers bought a new stake in shares of Inhibrx during the 4th quarter valued at approximately $228,000. Finally, New York State Common Retirement Fund acquired a new position in Inhibrx during the 4th quarter worth approximately $53,000. Institutional investors own 82.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Stock Performance

Shares of INBX stock opened at $14.35 on Friday. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $35.42. The stock’s fifty day simple moving average is $13.27 and its 200 day simple moving average is $14.64.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. On average, equities analysts anticipate that Inhibrx, Inc. will post 104.88 EPS for the current year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.